Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
April 22, 2024 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for...
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
April 11, 2024 10:03 ET
|
Ocuphire Pharma
LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire’s Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc....
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
April 01, 2024 07:14 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment...
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
March 08, 2024 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule...
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
February 23, 2024 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and...
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 15, 2024 16:10 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
February 14, 2024 08:00 ET
|
Ocuphire Pharma
Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief Financial Officer FARMINGTON HILLS, Mich., Feb. 14, 2024 (GLOBE...
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
February 05, 2024 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 24, 2024 16:10 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
January 04, 2024 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...